+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug of Abuse Screening Market - Global Forecast 2026-2032- Product Image
Drug of Abuse Screening Market - Global Forecast 2026-2032- Product Image
New

Drug of Abuse Screening Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6281445
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Drug-of-Abuse Screening: Executive Overview

Drug-of-abuse screening supports clinical care, workplace safety, forensic workflows, emergency response, and public-health surveillance. The field includes specimen collection, immunoassay and chromatographic testing, confirmatory laboratory analysis, and digitally enabled reporting. Demand is shaped by substance-use patterns, regulatory requirements, testing-program maturity, turnaround-time expectations, and the need for defensible results.

Testing Is Shifting Toward Faster, Broader, and More Defensible Workflows

The landscape is moving from isolated laboratory events toward integrated testing pathways. Point-of-care formats can shorten decision cycles, while laboratory confirmation remains important when results carry employment, legal, treatment, or safeguarding consequences. Panels are also adapting to changing substance patterns, and providers are placing greater emphasis on specimen validity, chain of custody, quality assurance, privacy, and clear interpretation of results.

Artificial Intelligence Strengthens Interpretation, Operations, and Quality Control

Artificial intelligence can support drug-of-abuse screening by prioritizing laboratory workloads, identifying atypical result patterns, assisting quality-control review, and improving workflow scheduling. Its value depends on representative validation data, transparent performance criteria, human oversight, and protection of sensitive health information. AI should augment-not replace-qualified interpretation, confirmatory testing, consent processes, and established rules for reporting non-negative findings.

Regional Priorities Reflect Differences in Regulation, Infrastructure, and Access

North America generally emphasizes formal workplace, clinical, forensic, and compliance workflows, with strong attention to confirmation and documentation. Europe combines mature laboratory practice with varied national rules on privacy, employment, and clinical use. Asia-Pacific spans advanced diagnostic systems and rapidly expanding access needs, making portability, affordability, and training important. Latin America is shaped by uneven laboratory capacity and the need for reliable decentralized testing. The Middle East places emphasis on regulated screening, occupational settings, and public safety, while Africa faces infrastructure, supply, workforce, and access constraints that make robust decentralized workflows especially relevant.

Economic and Security Groups Show Distinct Screening Priorities

ASEAN priorities include scalable access, cross-border consistency, and practical deployment across uneven health systems. BRICS members face diverse regulatory environments and differing laboratory maturity, creating demand for adaptable protocols and local capacity building. The European Union emphasizes privacy, analytical quality, and harmonization alongside national implementation. G7 settings typically prioritize advanced laboratory assurance, clinical governance, and data security. GCC countries often focus on regulated occupational, clinical, and public-safety applications. NATO members may require dependable screening procedures for readiness, occupational health, and secure operational environments, subject to national law and ethics requirements.

Country Context Determines Implementation and Governance

Australia emphasizes regulated clinical, workplace, and forensic practice across geographically dispersed settings. Brazil and Mexico require solutions that accommodate varied laboratory access and public-health needs. Canada and the United States place strong weight on documented procedures, privacy, confirmation, and program governance. China and India present substantial scale and regional diversity, increasing the importance of standardized quality systems and adaptable deployment. Japan and South Korea generally prioritize precision, reliability, and advanced laboratory integration. France, Germany, Italy, Spain, and the United Kingdom operate within mature healthcare and regulatory environments, while retaining distinct national rules for consent, employment, data handling, and evidentiary use. Russia requires attention to national regulatory procedures, laboratory governance, and operational continuity.

Build Trustworthy Screening Programs Before Expanding Automation

Industry leaders should map each use case to applicable consent, privacy, employment, clinical, and evidentiary requirements. They should establish specimen-validity controls, documented chain of custody, confirmatory pathways, proficiency testing, and clear escalation rules before deploying at scale. A tiered model can combine rapid screening with laboratory confirmation where consequences are significant. AI investments should begin with narrowly defined, auditable tasks and prospective validation. Training, external quality assessment, secure interoperability, and equitable access should be treated as core program capabilities rather than optional enhancements.

Methodology: Structured Synthesis of Screening-System Evidence

This executive summary uses a structured market-analysis approach focused on the drug-of-abuse screening value chain. The assessment considers testing modalities, specimen types, workflow stages, application settings, regulatory and quality requirements, digital capabilities, regional conditions, and country-level implementation factors. Findings are synthesized from verifiable public evidence and established industry practices, with emphasis on qualitative drivers and operational implications. No market estimates, shares, forecasts, or company-specific claims are used.

Reliable Results Depend on Integrated Science, Governance, and Access

Drug-of-abuse screening is becoming a more connected discipline in which analytical performance, turnaround time, data governance, and responsible interpretation must advance together. Regional and country differences mean that a single deployment model will not fit every setting. Organizations that combine validated technology with strong quality systems, appropriate confirmation, trained personnel, privacy safeguards, and transparent oversight will be best positioned to deliver useful and defensible screening outcomes.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drug of Abuse Screening Market, by Product Type
7.1. Introduction
7.2. Analyzers
7.3. Rapid Test Kits
7.4. Consumables & Reagents
7.5. Software Solutions
8. Drug of Abuse Screening Market, by Technology
8.1. Introduction
8.2. Immunoassay
8.3. Chromatography
8.4. Spectroscopy
9. Drug of Abuse Screening Market, by End-Use Industry
9.1. Introduction
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Forensic Laboratories
9.5. Academic & Research Institutions
10. Drug of Abuse Screening Market, by Region
10.1. Introduction
10.2. Asia-Pacific
10.3. North America
10.4. Latin America
10.5. Europe
10.6. Middle East
10.7. Africa
11. Drug of Abuse Screening Market, by Group
11.1. Introduction
11.2. ASEAN
11.3. GCC
11.4. European Union
11.5. BRICS
11.6. G7
11.7. NATO
12. Drug of Abuse Screening Market, by Country
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. United Kingdom
12.7. Germany
12.8. France
12.9. Russia
12.10. Italy
12.11. Spain
12.12. China
12.13. India
12.14. Japan
12.15. Australia
12.16. South Korea
13. Competitive Landscape
13.1. Market Share Analysis, 2025
13.2. Market Concentration Analysis, 2025
13.2.1. Concentration Ratio (CR)
13.2.2. Herfindahl Hirschman Index (HHI)
13.3. Recent Developments & Impact Analysis, 2025
13.4. Product Portfolio Analysis, 2025
13.5. Benchmarking Analysis, 2025
14. Company Profiles
14.1. Abbott Laboratories
14.2. Alfa Scientific Designs, Inc.
14.3. Assure Tech (Hangzhou) Co., Ltd.
14.4. Beijing Hotgen Biotech Co., Ltd.
14.5. Bio-Rad Laboratories, Inc.
14.6. Danaher Corporation
14.7. Drägerwerk AG & Co. KGaA
14.8. F. Hoffmann-La Roche Ltd
14.9. Guangzhou Wondfo Biotech Co., Ltd.
14.10. Hangzhou Biotest Biotech Co., Ltd.
14.11. Lifeloc Technologies, Inc.
14.12. Omega Laboratories, Inc.
14.13. OraSure Technologies, Inc.
14.14. Premier Biotech, Inc.
14.15. Psychemedics Corporation
14.16. RunBio Biotechnology Co., Ltd.
14.17. Shimadzu Corporation
14.18. Siemens Healthineers AG
14.19. Thermo Fisher Scientific Inc.
14.20. Zhejiang Orient Gene Biotech Co., Ltd.
15. Key Experts
LIST OF FIGURES
FIGURE 1. Global Drug of Abuse Screening Market, Years Considered for the Study
FIGURE 2. Global Drug of Abuse Screening Market, Research Design
FIGURE 3. Global Drug of Abuse Screening Market, Research Framework
FIGURE 4. Global Drug of Abuse Screening Market, Data Triangulation
FIGURE 5. Global Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Drug of Abuse Screening Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Drug of Abuse Screening Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Drug of Abuse Screening Market Size, by Technology, 2025 vs 2032 (%)
FIGURE 9. Global Drug of Abuse Screening Market Size, by Technology, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Drug of Abuse Screening Market Size, by End-Use Industry, 2025 vs 2032 (%)
FIGURE 11. Global Drug of Abuse Screening Market Size, by End-Use Industry, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Drug of Abuse Screening Market Size, by Region, 2025 vs 2032 (%)
FIGURE 13. Global Drug of Abuse Screening Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Drug of Abuse Screening Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 15. Global Drug of Abuse Screening Market Size, by Country, 2025 vs 2032 (%)
FIGURE 16. Global Drug of Abuse Screening Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Drug of Abuse Screening Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Drug of Abuse Screening Market Segmentation & Coverage
TABLE 2. Global Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 3. Global Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Analyzers Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Analyzers Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Analyzers Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Rapid Test Kits Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Rapid Test Kits Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Rapid Test Kits Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Consumables & Reagents Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Consumables & Reagents Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Consumables & Reagents Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Software Solutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Software Solutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Software Solutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 17. Global Immunoassay Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Immunoassay Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Immunoassay Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Chromatography Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Chromatography Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Chromatography Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Spectroscopy Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Spectroscopy Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Spectroscopy Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 27. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Diagnostic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Diagnostic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Diagnostic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Forensic Laboratories Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Forensic Laboratories Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Forensic Laboratories Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Academic & Research Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Academic & Research Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Academic & Research Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Asia-Pacific Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Asia-Pacific Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 42. Asia-Pacific Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 43. Asia-Pacific Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 44. North America Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. North America Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 46. North America Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 47. North America Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 48. Latin America Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Latin America Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 50. Latin America Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 51. Latin America Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 52. Europe Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Europe Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 54. Europe Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 55. Europe Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 56. Middle East Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Middle East Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 58. Middle East Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 59. Middle East Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 60. Africa Drug of Abuse Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Africa Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 62. Africa Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 63. Africa Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 64. Global Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. ASEAN Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. ASEAN Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 67. ASEAN Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 68. ASEAN Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 69. GCC Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. GCC Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 71. GCC Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 72. GCC Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 73. European Union Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. European Union Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 75. European Union Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 76. European Union Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 77. BRICS Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. BRICS Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 79. BRICS Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 80. BRICS Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 81. G7 Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. G7 Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 83. G7 Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 84. G7 Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 85. NATO Drug of Abuse Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. NATO Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 87. NATO Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 88. NATO Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 89. Global Drug of Abuse Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. United States Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 91. United States Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 92. United States Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 93. United States Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 94. Canada Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 95. Canada Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 96. Canada Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 97. Canada Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 98. Mexico Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 99. Mexico Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 100. Mexico Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 101. Mexico Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 102. Brazil Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 103. Brazil Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 104. Brazil Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 105. Brazil Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 106. United Kingdom Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 107. United Kingdom Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 108. United Kingdom Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 109. United Kingdom Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 110. Germany Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 111. Germany Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. Germany Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 113. Germany Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 114. France Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 115. France Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 116. France Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 117. France Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 118. Russia Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 119. Russia Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 120. Russia Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 121. Russia Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 122. Italy Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 123. Italy Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 124. Italy Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 125. Italy Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 126. Spain Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 127. Spain Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 128. Spain Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 129. Spain Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 130. China Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 131. China Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 132. China Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 133. China Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 134. India Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 135. India Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 136. India Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 137. India Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 138. Japan Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 139. Japan Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 140. Japan Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 141. Japan Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 142. Australia Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 143. Australia Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 144. Australia Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 145. Australia Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 146. South Korea Drug of Abuse Screening Market Size, 2017-2032 (USD Million)
TABLE 147. South Korea Drug of Abuse Screening Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 148. South Korea Drug of Abuse Screening Market Size, by Technology, 2017-2032 (USD Million)
TABLE 149. South Korea Drug of Abuse Screening Market Size, by End-Use Industry, 2017-2032 (USD Million)
TABLE 150. Global Drug of Abuse Screening Market Share, by Key Player, 2025
TABLE 151. Global Drug of Abuse Screening Market, Key Experts

Companies Mentioned

  • Abbott Laboratories
  • Alfa Scientific Designs, Inc.
  • Assure Tech (Hangzhou) Co., Ltd.
  • Beijing Hotgen Biotech Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Drägerwerk AG & Co. KGaA
  • F. Hoffmann-La Roche Ltd
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hangzhou Biotest Biotech Co., Ltd.
  • Lifeloc Technologies, Inc.
  • Omega Laboratories, Inc.
  • OraSure Technologies, Inc.
  • Premier Biotech, Inc.
  • Psychemedics Corporation
  • RunBio Biotechnology Co., Ltd.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Orient Gene Biotech Co., Ltd.

Related Topics

Related Reports

Drug of Abuse Testing Market - Global Forecast 2026-2032 - Product Image

Drug of Abuse Testing Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Drug of Abuse Test Device Market - Global Forecast 2026-2032 - Product Image

Drug of Abuse Test Device Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
At-home Drug of Abuse Testing Market - Global Forecast 2026-2032 - Product Image

At-home Drug of Abuse Testing Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Breathalyzers Market Report and Forecast 2024-2032 - Product Image

Breathalyzers Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Drug of Abuse Testing Market (By Product Type, Sample / Test Type, Drug Type, End Users / Setting Type, Country Analysis), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2032 - Product Image

Drug of Abuse Testing Market (By Product Type, Sample / Test Type, Drug Type, End Users / Setting Type, Country Analysis), Regulatory Status, Recent Developments, Company Profiles - Forecast to 2032

  • Report
  • 235 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.